Jpmorgan Chase & CO Harvard Bioscience Inc Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Harvard Bioscience Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 113,591 shares of HBIO stock, worth $87,465. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,591
Previous 29,501
285.04%
Holding current value
$87,465
Previous $79,000
202.53%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding HBIO
# of Institutions
97Shares Held
31.3MCall Options Held
0Put Options Held
15K-
Black Rock Inc. New York, NY2.84MShares$2.19 Million0.0% of portfolio
-
Punch & Associates Investment Management, Inc. Edina, MN2.76MShares$2.12 Million0.35% of portfolio
-
Harvey Partners, LLC Tarrytown, NY2.68MShares$2.07 Million0.66% of portfolio
-
Amh Equity LTD2.5MShares$1.93 Million5.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.16MShares$1.66 Million0.0% of portfolio
About HARVARD BIOSCIENCE INC
- Ticker HBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 41,636,500
- Market Cap $32.1M
- Description
- Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as w...